S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Intra-Cellular TherapiesBasilea PharmaceuticaRetrophinMyovant SciencesViking Therapeutics
SymbolNASDAQ:ITCIOTCMKTS:BPMUFNASDAQ:RTRXNYSE:MYOVNASDAQ:VKTX
Price Information
Current Price$8.22$42.28$11.25$5.35$6.62
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$25.14N/A$29.71$24.50$19.79
% Upside from Price Target205.87% upsideN/A164.13% upside357.94% upside198.88% upside
Trade Information
Market Cap$455.15 million$501.86 million$480.23 million$496.50 million$478.04 million
Beta1.161.080.80.92.31
Average Volume705,1193486,420239,5792,198,941
Sales & Book Value
Annual Revenue$250,000.00$103.15 million$164.25 millionN/AN/A
Price / Sales1,814.094.872.94N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.81 per share($3.55) per share$7.72 per share$0.06 per share$4.17 per share
Price / Book1.41-11.911.46N/AN/A
Profitability
Net Income$-155,130,000.00$-19,670,000.00$-102,680,000.00$-273,550,000.00$-22,060,000.00
EPS($2.84)N/A($2.54)($4.09)($0.40)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/A4,228.00N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-83.94%N/AN/A
Return on Equity (ROE)-50.81%N/A-47.21%-545.73%-8.27%
Return on Assets (ROA)-44.29%N/A-20.67%-140.77%-8.12%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.08%N/A0.72%1.24%N/A
Current Ratio8.86%N/A5.05%3.42%52.19%
Quick Ratio8.86%N/A4.99%3.42%52.19%
Ownership Information
Institutional Ownership Percentage68.95%N/AN/A40.29%62.58%
Insider Ownership Percentage18.20%N/A4.32%3.00%3.49%
Miscellaneous
Employees732272148615
Shares Outstanding55.17 million11.87 million42.95 million89.62 million72.21 million
Next Earnings Date11/6/2019 (Estimated)N/A11/7/2019 (Estimated)11/14/2019 (Estimated)11/6/2019 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
 Intra-Cellular TherapiesBasilea PharmaceuticaRetrophinMyovant SciencesViking Therapeutics

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel